PR99212

LISBON, Portugal, Dec. 14, 2022, /PRNewswire=KYODO JBN/ --

Hovione and GEA today announced a strategic collaboration to advance Continuous

Tableting. This partnership stemmed from a successful customer-supplier

relationship spanning several years. It combines GEA´s engineering expertise

with Hovione´s development and manufacturing experience and both parties commit

to partner to accelerate the adoption of Continuous Tableting technology.

The advantages of continuous over batch manufacturing are well known.

Continuous production systems allow for leaner and risk-reduced development

paths, leaner supply chains, increased built-in quality, and in general,

manufacturing processes of greater flexibility and reduced complexity. In the

context of this strategic collaboration, Hovione and GEA will combine their

strengths to further advance the technology and contribute to the establishment

of new standards and new levels of market acceptance.

"Hovione has a track record in industrializing and democratizing emerging

pharmaceutical technologies, such as amorphous solid dispersions by spray

drying, and turn them into dependable and scalable offerings that are available

to all." Says Jean-Luc Herbeaux, CEO of Hovione. He adds "We have been

committed to Continuous Tableting for the last 7 years and we are now ready to

contribute decisively to the advancement of one of the most promising

technologies in pharma manufacturing. This collaboration with GEA, gives us the

opportunity to link up with a leading designer and supplier of Continuous

Tableting equipment solutions and bring Continuous Tableting to the next levels

of reliability, flexibility and adoption."

Navin Lakhanpaul, Global Head Pharma-Solid Dosage, GEA, adds: "As a leading

supplier of process technology, GEA has established itself as a trusted

solution provider in the pharmaceutical industry, and as a pioneer in the

development of Continuous Tableting technology." He adds "Our relationship with

Hovione over many years has clearly demonstrated the value in further

collaborating and developing synergies in our respective areas of expertise. We

share a common objective of enabling the wider use of Continuous Tableting in

the Pharmaceutical Industry, and firmly believe that our partnership with

Hovione will accelerate the growth of this exciting technology."

About Hovione

Hovione is an international company with over 60 years of experience as a

Contract Development and Manufacturing Organization (CDMO) [

https://www.hovione.com/products-and-services/contract-manufacturing-services ]

with a fully integrated offering of services for drug substance, drug product

intermediate and drug product. The company has four FDA inspected sites [

https://www.hovione.com/hovione-worldwide ] in the USA, Portugal, Ireland and

China as well as development laboratories in Lisbon, Portugal and New Jersey,

USA. Hovione provides pharmaceutical customers services for the development and

compliant manufacture [

https://www.hovione.com/products-and-services/contract-manufacturing-services/particle-engineering

] of innovative drugs, including highly potent compounds, and customized

product solutions across the entire drug life cycle. In the inhalation area,

Hovione is the only independent company offering a complete range of services,

from API to formulation development and devices. Hovione is a company with a

culture based on innovation, quality and delivery. Hovione was the first

Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of

Rx-360, EFCG and participates actively in industry quality improvement

initiatives to lead new global industry standards.

About GEA

GEA is one of the world's largest suppliers of systems and components to the

food, beverage and pharmaceutical industries. The international technology­

group, founded in 1881, focuses on machinery and plants, as well as advanced

process technology, components, and comprehensive services. With more than

18,000 employees working across five divisions and 62 countries, the group

generated revenues of more than EUR 4.7 billion in fiscal year 2021. GEA

plants, processes, components and services enhance the efficiency and

sustainability of production processes across the globe. They contribute

significantly to the reduction of CO2 emissions, plastic usage and food waste.

In doing so, GEA makes a key contribution toward a sustainable future, in line

with the company's purpose: "Engineering for a better world".

GEA is listed in the German MDAX and the STOXX® Europe 600 Index and is also

among the companies comprising the DAX 50 ESG and MSCI Global Sustainability

Indices.

For more information, please visit www.hovione.com or contact:

Vanessa Romeu | Communications Director | vromeu@hovione.com |Tel.: +351 21 982

9000

Photo - https://mma.prnewswire.com/media/1968158/Hovione_signed.jpg

Photo -

https://mma.prnewswire.com/media/1968159/Continuous_Tableting_Hovione.jpg

Source: HOVIONE